US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prospect Capital Corp

25.06

+0.0000

Volume:- -

Turnover:319.71K

Market Cap:9.22B

PE:68.17

High:25.06

Open:25.06

Low:25.06

Close:25.06

Loading ...

Overview Company News Filings

Strategic Wins and Cost Management Boost Planet Labs PBC’s Growth Prospects Amid Challenges

Planet Labs PBC (PL) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic AI Expansion

Planet Labs PBC options imply 23.3% move in share price post-earnings

Planet Labs PBC Price Target Raised to $4.50/Share From $4.00 by JMP Securities

JMP Securities Reaffirms Their Buy Rating on Planet Labs PBC (PL)

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

John Munday named CEO of Colliers UK

Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?

Sunshine Biopharma Launches a New Generic Prescription Drug

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients

Alphabet's Partnership with Anthropic PBC Exempt from Competition and Markets Authority Merger Investigation in UK

MT Newswires Live

GSK’s Linerixibat Shows Promise for PBC Itch Relief

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

Ipsen’s Iqirvo Gains Ground in PBC Treatment

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

BRIEF-Danone S.A. - Danone North America PBC Sent Second Letter To Lifeway Foods In Order To Express Disappointment In Board’s Response To Initial Proposal

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PBC/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PBC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBC\",,,,,undefined,":{"symbol":"PBC","market":"US","secType":"STK","nameCN":"Prospect Capital Corp","latestPrice":25.06,"timestamp":1640811600000,"preClose":25.06,"halted":4,"volume":0,"delay":0,"floatShares":0,"shares":367817926,"eps":0.367626,"marketStatus":"Delisted","change":0,"latestTime":"04-17 17:51:02 EDT","open":25.06,"high":25.06,"low":25.06,"amount":319705.1613,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.367626,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1744934400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":25.06,"dividendRate":0.028731,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBC\",,,,,undefined,":{"symbol":"PBC","floatShares":0,"roa":"4.83%","roe":"4.16%","lyrEps":0.394789,"shares":367817926,"dividePrice":0.72,"high":25.06,"amplitude":0,"preClose":25.06,"low":25.06,"week52Low":25,"pbRate":"2.90","week52High":26.49,"institutionHeld":0,"latestPrice":25.06,"eps":0.367626,"divideRate":0.028731,"volume":0,"delay":0,"ttmEps":0.367626,"open":25.06},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBC\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2490096537","title":"Strategic Wins and Cost Management Boost Planet Labs PBC’s Growth Prospects Amid Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2490096537","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490096537?lang=en_us&edition=fundamental","pubTime":"2024-12-10 19:16","pubTimestamp":1733829368,"startTime":"0","endTime":"0","summary":"Planet Labs PBC (PL – Research Report), the Industrials sector company, was revisited by a Wall Street analyst today. Analyst Ryan Koontz from Need...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/strategic-wins-and-cost-management-boost-planet-labs-pbcs-growth-prospects-amid-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/strategic-wins-and-cost-management-boost-planet-labs-pbcs-growth-prospects-amid-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBC"],"gpt_icon":0},{"id":"2490944110","title":"Planet Labs PBC (PL) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic AI Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2490944110","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490944110?lang=en_us&edition=fundamental","pubTime":"2024-12-10 19:00","pubTimestamp":1733828440,"startTime":"0","endTime":"0","summary":"Non-GAAP Gross Margin: 64%, up from 52% a year ago and 58% last quarter.Adjusted EBITDA Loss: Approximately $242,000, marking the sixth sequential quarter of improvement.Defense and Intelligence Sector Revenue Growth: Approximately 25% year-over-year.Civil Government Sector Revenue Growth: Approximately 10% year-over-year.Net Dollar Retention Rate: 104%, impacted by a delayed NASA task order.Cash, Cash Equivalents, and Short-term Investments: Approximately $242 million.Remaining Performance Obligations : Approximately $146 million, up 30% quarter-over-quarter.Q4 Revenue Guidance: Expected to be between $61 million and $63 million.Q4 Non-GAAP Gross Margin Guidance: Expected to be between 63% and 65%.Q4 Adjusted EBITDA Profit Guidance: Expected to be between $0 and $2 million.Planet Labs PBC  achieved a record $61.3 million in revenue for Q3 fiscal 2025, marking an 11% year-on-year growth.Planet Labs PBC  is leveraging AI to drive pipeline growth and enhance customer value, with signific","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/planet-labs-pbc-pl-q3-110040771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PL","PBC"],"gpt_icon":0},{"id":"2490358701","title":"Planet Labs PBC options imply 23.3% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2490358701","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490358701?lang=en_us&edition=fundamental","pubTime":"2024-12-10 02:50","pubTimestamp":1733770208,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in Planet Labs (PL) PBC is 1.4x normal with calls leading puts 19:5. Implied volatility suggests the market is anticipa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/planet-labs-pbc-options-imply-23-3-move-in-share-price-post-earnings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/planet-labs-pbc-options-imply-23-3-move-in-share-price-post-earnings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBC"],"gpt_icon":0},{"id":"2490772266","title":"Planet Labs PBC Price Target Raised to $4.50/Share From $4.00 by JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2490772266","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490772266?lang=en_us&edition=fundamental","pubTime":"2024-12-10 00:18","pubTimestamp":1733761080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2024 11:18 ET (16:18 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBC","PL","JMP"],"gpt_icon":0},{"id":"2490718044","title":"JMP Securities Reaffirms Their Buy Rating on Planet Labs PBC (PL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2490718044","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490718044?lang=en_us&edition=fundamental","pubTime":"2024-12-09 13:45","pubTimestamp":1733723109,"startTime":"0","endTime":"0","summary":"In a report released today, Trevor J. Walsh from JMP Securities reiterated a Buy rating on Planet Labs PBC (PL – Research Report), with a price tar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jmp-securities-reaffirms-their-buy-rating-on-planet-labs-pbc-pl-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jmp-securities-reaffirms-their-buy-rating-on-planet-labs-pbc-pl-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JMP","PBC","PL"],"gpt_icon":0},{"id":"2489526152","title":"Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2489526152","media":"ACCESSWIRE","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489526152?lang=en_us&edition=fundamental","pubTime":"2024-12-07 05:15","pubTimestamp":1733519700,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc.  , a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement.The agreement includes the issuance of 961,446 shares of common stock  and warrants to purchase up to an additional 480,723 shares of common stock. Each share  is priced at $2.10 and is accompanied by a warrant. The warrants will have an exercise price of $2.031 per share, becoming exercisable six months after issuance and expiring five and one-half years from the date of issuance. The closing of this transaction is expected on or about December 9, 2024, subject to customary closing conditions.The securities in this private placement were offered under Section 4 of the Securities Act of 1933, as amended, and Regulation D thereunder. The shares of common stock and un","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-announces-2-02-million-211500097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PBC","THAR"],"gpt_icon":0},{"id":"2488166443","title":"John Munday named CEO of Colliers UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2488166443","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488166443?lang=en_us&edition=fundamental","pubTime":"2024-12-04 19:00","pubTimestamp":1733310000,"startTime":"0","endTime":"0","summary":"John Munday will be promoted to Chief Executive Officer  of Colliers UK, effective 3 March 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/04/2991283/0/en/John-Munday-named-CEO-of-Colliers-UK.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBC","CEO","BK4079","CIGI"],"gpt_icon":0},{"id":"2487901085","title":"Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?","url":"https://stock-news.laohu8.com/highlight/detail?id=2487901085","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487901085?lang=en_us&edition=fundamental","pubTime":"2024-11-30 02:50","pubTimestamp":1732906200,"startTime":"0","endTime":"0","summary":"Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It has grown steadily in the past six months.Earlier this month, Gilead reported better-than-expected third-quarter results and raised its annual earnings guidance yet again. Revenues increased 7% from the year-ago quarter’s level due to high HIV and Veklury sales.Approval of new drugs and encouraging pipeline progress have also boosted investors’ sentiment of late.With a market share of more than 49% in the United States at the end of the third quarter, its flagship HIV therapy, Biktarvy, continues to maintain its strong growth, thereby fueling the top line. The strong momentum in Biktarvy has enabled Gilead to increase its HIV sales target to 5% in 2024 from the earlier estimate of 4%.Adjusted EPS is now anticipated to be in the range of $4.25-$4.45, up from th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2Uxrul9Xalj9HwUZqlOfZA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2Uxrul9Xalj9HwUZqlOfZA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-stock-surges-44-2-185000541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756325.SGD","LU1037948541.HKD","LU1989771016.USD","BK4559","LU0965509010.AUD","IE00BLSP4452.SGD","LU1917777945.USD","IE00BKVL7J92.USD","BK4585","LU1585245621.USD","SGXZ57979304.SGD","LU1037948897.HKD","LU2089984988.USD","LU2468319806.SGD","LU1941712264.USD","LU1066051811.HKD","PBC","IE00B2B36J28.USD","IE00B19Z3B42.SGD","GSK","LU1093756168.USD","LU1934455194.USD","MRK","GSK.UK","LU2361044949.HKD","BK4550","LU0861579265.USD","IE0002270589.USD","IE0009355771.USD","LU0320765992.SGD","LU1934455863.HKD","BK4566","LU0234572021.USD","LU1571399168.USD","LU0006306889.USD","SG9999002224.SGD","IE00BJT1NW94.SGD","SG9999014542.SGD","SG9999014567.USD","LU0234570918.USD","LU0965509101.SGD","LU2324357040.USD","IE00BSNM7G36.USD","BK4568","LU0122379950.USD","LU0106261372.USD","LU1941712348.USD","GILD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2485509242","title":"Sunshine Biopharma Launches a New Generic Prescription Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2485509242","media":"ACCESSWIRE","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485509242?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:00","pubTimestamp":1732280400,"startTime":"0","endTime":"0","summary":"FORT LAUDERDALE, FL / ACCESSWIRE / November 22, 2024 / Sunshine Biopharma Inc.  , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched a new generic prescription drug.\"This is the third new product we have introduced this year. We continue to grow through the addition of new products to strengthen our presence in the Canadian generic drugs market which was estimated to be $9.7 billion in 2023 and is projected to grow to $19.2 billion by 2032,\" said Dr. Steve Slilaty, CEO of Sunshine Biopharma.This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc.  that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mScQLFDd6Wi_khGmrT_H9A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/0eab2749b8d945abe59384a0a288e27c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mScQLFDd6Wi_khGmrT_H9A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/0eab2749b8d945abe59384a0a288e27c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sunshine-biopharma-launches-generic-prescription-130000075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4159","SBFM","BK4139","CAGR","SBFMW","PBC"],"gpt_icon":0},{"id":"2485949562","title":"Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2485949562","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485949562?lang=en_us&edition=fundamental","pubTime":"2024-11-21 21:00","pubTimestamp":1732194000,"startTime":"0","endTime":"0","summary":"MORRISVILLE, N.C., Nov.  21, 2024  (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare diseas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/21/2985154/0/en/Science-37-Nearly-Doubles-U-S-Enrollment-for-GSK-Phase-3-Rare-Disease-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK.UK","BK4007","LU1829250122.USD","BK4532","BK4588","PBC","GSK","BK4585"],"gpt_icon":0},{"id":"2484971418","title":"GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2484971418","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484971418?lang=en_us&edition=fundamental","pubTime":"2024-11-20 02:24","pubTimestamp":1732040656,"startTime":"0","endTime":"0","summary":"On Tuesday, GSK plc  released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in adults with cholestatic pruritus  associated with primary biliary cholangitis , a rare autoimmune liver disease.GLISTEN met its primary endpoint, with linerixibat improving itch, as demonstrated by a statistically significant reduction from baseline in monthly itch score over 24 weeks versus placebo.Also Read: GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market – Here’s Why. The trial recruited PBC patients with moderate to severe itch who were receiving stable doses of guideline-suggested therapies for pruritus, were treatment nave, or had been previously treated.The preliminary safety results are generally consistent with those seen in prior studies of linerixibat. Further analysis of these data is ongoing.People who have been diagnosed with PBC will reach 510,000 globally by 2030, and more than 240,000 people will experience relentless itch","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pG_Y.M3QkKyixiGDmtURDA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/d0ed0f9470b88069294682599fa24b60","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pG_Y.M3QkKyixiGDmtURDA--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/d0ed0f9470b88069294682599fa24b60"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gsks-investigational-liver-disease-candidate-182416125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","BK4585","GSK.UK","IE00BFMHRM44.USD","BK4566","BK4532","LU1829250122.USD","SSI","BK4588","GSK","PBC","NICE","BK4007"],"gpt_icon":0},{"id":"2484946461","title":"Alphabet's Partnership with Anthropic PBC Exempt from Competition and Markets Authority Merger Investigation in UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2484946461","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484946461?lang=en_us&edition=fundamental","pubTime":"2024-11-19 21:01","pubTimestamp":1732021262,"startTime":"0","endTime":"0","summary":"Alphabet's (GOOG) partnership with AI safety and research firm Anthropic PBC does not meet the criteria for a relevant merger situation under United Kingdom law and does not require further investigat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1069347547.HKD","IE00B4JS1V06.HKD","LU1035775433.USD","PBC","SG9999018857.SGD","BK4534","LU0048573561.USD","GOOG","LU0238689110.USD","LU1815336760.USD","LU2125154778.USD","IE0004445239.USD","LU0323591593.USD","LU1429558221.USD","LU0965509101.SGD","LU0154236417.USD","LU0006306889.USD","BK4532","LU2463028550.USD","LU0314104364.USD","IE00B775SV38.USD","LU2430703095.HKD","LU2242650005.HKD","LU0345774391.USD","LU1974910355.USD","BK4561","LU2065171402.SGD","IE00BKPKM429.USD","SG9999015952.SGD","LU1221951129.SGD","LU1267930730.SGD","LU1935042991.SGD","LU2326559502.SGD","LU0149725797.USD","LU1244550494.USD","LU2023250843.SGD","GOOGL","LU0310800965.SGD","LU1037948897.HKD","LU2265009873.SGD","LU0170899867.USD","LU0965508806.USD","IE00BJTD4N35.SGD","LU0320765059.SGD","LU1303367103.USD","LU0557290698.USD","LU1804176565.USD","LU0128525929.USD","SG9999000418.SGD","LU2063271972.USD"],"gpt_icon":1},{"id":"2484960392","title":"GSK’s Linerixibat Shows Promise for PBC Itch Relief","url":"https://stock-news.laohu8.com/highlight/detail?id=2484960392","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484960392?lang=en_us&edition=fundamental","pubTime":"2024-11-19 15:10","pubTimestamp":1732000259,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline (GB:GSK) has released an update. GlaxoSmithKline (GSK) has announced promising Phase III trial results for linerixibat, a potential...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-linerixibat-shows-promise-for-pbc-itch-relief?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-linerixibat-shows-promise-for-pbc-itch-relief?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","GSK.UK","PBC","BK4588","GSK","BK4007","LU1829250122.USD","BK4585"],"gpt_icon":0},{"id":"2484622121","title":"Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2484622121","media":"ACCESSWIRE","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484622121?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:00","pubTimestamp":1731934800,"startTime":"0","endTime":"0","summary":"Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse events. Phase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025. BRIDGEWATER, NJ / ACCESSWIRE / November 18, 2024 / Tharimmune, Inc.  , a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, presented new TH104 clinical data at the American Association for the Study of Liver Disease  The Liver Meeting 2024, underway in San Diego from November 15-19. The Phase 1 trial was a single-dose, single-center, open-label, randomized study of TH104 transmucosal buccal film conducted in two cohorts of patients with chronic liver disease , with the primary outcome of safety and tolerability.This study screened 19 patients and 12 were enrolled with two types of CLD categorized as Child-Pugh A  and Child-Pugh B . The Child-Pugh score is a system for assessing ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UZTpE1I7SAphgBk547xy2A--~B/aD00Mzk7dz00MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/f703bc8c191cae054ccd693dc3d4af55","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UZTpE1I7SAphgBk547xy2A--~B/aD00Mzk7dz00MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/f703bc8c191cae054ccd693dc3d4af55"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-presents-positive-clinical-data-130000509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","BK4181","PBC","THAR","BK4232","BK4139","R","PK","BK4218"],"gpt_icon":0},{"id":"2483063589","title":"Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2483063589","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483063589?lang=en_us&edition=fundamental","pubTime":"2024-11-16 03:14","pubTimestamp":1731698075,"startTime":"0","endTime":"0","summary":"On Friday, Gilead Sciences, Inc. revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term efficacy and safety of Livdelzi.The study showed that 81%  of participants with primary biliary cholangitis  treated with Livdelzi achieved a composite biochemical response , demonstrating significant improvements in a key measures of PBC progression.Additionally, 41%  of participants achieved normalization of alkaline phosphatase  levels, a critical biomarker of liver function.Also Read: HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook. Livdelzi continues to appear generally well tolerated, with no new safety signals or change in frequency of adverse events  with up to three years of exposure.In August, the FDA granted accelerated approval forGilead’s Livdelzifor primary biliary cholangitis in combination with ursodeoxycholic acid  in adults who have had an inadequate","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3hk2DfPaNG6bpP8wuKJbsQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/fa17fef69415d46f43dbb74820aa893b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3hk2DfPaNG6bpP8wuKJbsQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/fa17fef69415d46f43dbb74820aa893b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-unveils-long-term-data-191435289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0058720904.USD","BK4583","LU2468319806.SGD","IE00BSNM7G36.USD","LU1066053197.SGD","LU0889565916.HKD","IE00BKVL7J92.USD","LU1066051498.USD","LU1430594728.SGD","BK4532","BK4139","BK4568","LU0234570918.USD","IE0002270589.USD","GILD","BK4585","LU0109394709.USD","IE00B19Z3581.USD","BK4578","LU0289739699.SGD","LU1585245621.USD","BK4588","LU1839511570.USD","IE00B19Z3B42.SGD","BK4566","PBC","LU1571399168.USD","IE00BZ1G4Q59.USD","LU2087621335.USD","BK4550","LU0320765992.SGD"],"gpt_icon":0},{"id":"2483304885","title":"Ipsen’s Iqirvo Gains Ground in PBC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2483304885","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483304885?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:34","pubTimestamp":1731688449,"startTime":"0","endTime":"0","summary":"Ipsen (FR:IPN) has released an update. Ipsen’s Iqirvo (elafibranor) shows promising long-term efficacy and safety in treating primary biliary chola...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ipsens-iqirvo-gains-ground-in-pbc-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ipsens-iqirvo-gains-ground-in-pbc-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBC"],"gpt_icon":0},{"id":"2483306790","title":"Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus","url":"https://stock-news.laohu8.com/highlight/detail?id=2483306790","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483306790?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:00","pubTimestamp":1731686400,"startTime":"0","endTime":"0","summary":"Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024. Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 2024 and in the U.K. in October 2024. PARIS, FRANCE, 15 November 2024 Ipsen  announced today late-breaking data for Iqirvo  from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American Association for the Study of Liver Disease  congress. The late-breaking presentations  report on biomarkers of cholestasis, stabilization of surrogate markers of liver fibrosis and moderate-to-severe pruritus data for up to three years in Iqirvo-treated patients. Additionally, exploratory endpoints in fatigue and sleep were evaluated using patient-reported outcomes tools.The impact of Iqirvo on fatigue and sleep were investigated as an","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NGuJAdc3cTnVKJwSV6LVjQ--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0859d3e9de29c3c0ec9ff9c9af29edb9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NGuJAdc3cTnVKJwSV6LVjQ--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/0859d3e9de29c3c0ec9ff9c9af29edb9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/iqirvo-elafibranor-data-shows-efficacy-160000898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","PBC","IPSEF","PRO","IPSEY","BK4166","BK4215","ESS","ML","BK4585","BK4588","BK4023"],"gpt_icon":0},{"id":"2483371767","title":"BRIEF-Danone S.A. - Danone North America PBC Sent Second Letter To Lifeway Foods In Order To Express Disappointment In Board’s Response To Initial Proposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2483371767","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483371767?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:14","pubTimestamp":1731680073,"startTime":"0","endTime":"0","summary":"Nov 15  - Lifeway Foods Inc   :   * DANONE S.A. - DANONE NORTH AMERICA PBC SENT SECOND LETTER TO LIFEWAY FOODS IN ORDER TO EXPRESS DISAPPOINTMENT IN BOARD’S RESPONSE TO INITIAL PROPOSAL   * DANONE S.A. - LETTER TO LIFEWAY FOODS REITERATE DANONE NORTH AMERICA PBC’S STRONG COMMITMENT TO THE PROPOSED TRANSACTION   * DANONE SA - IN UPDATED PROPOSAL, DANONE NORTH AMERICA PBC INCREASED OFFER FOR PROPOSED TRANSACTION FROM $25.00 PER SHARE TO $27.00 PER SHARE   * DANONE SA - INTEND TO ENGAGE IN DISCUSSIONS WITH LIFEWAY FOODS REGARDING TERMS OF PROPOSED TRANSACTION   * DANONE SA-PROPOSED DEAL WOULD BE WHOLLY FUNDED IN CASH FROM EXISTING CASH RESERVES OF REPORTING PERSONS,NOT CONTINGENT ON ANY FINANCING REQUIREMENTSSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LWAY","PBC","BK4212"],"gpt_icon":0},{"id":"2483863504","title":"GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483863504","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483863504?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:10","pubTimestamp":1731532200,"startTime":"0","endTime":"0","summary":"Ipsen to present new data on elafibranor at The Liver Meeting 2024. Launch of Iqirvo 1 on track with expectations; encouraging feedback from healthcare providers and payers in the U.S.UK NICE reimbursement approved and first reimbursed sales in Germany in October 2024. Next 26.5M milestone payment by Ipsen pending a third pricing and reimbursement approval in Europe. Scientific progress in ACLF to be featured at The Liver Meeting 2024, with 4 posters presenting new preclinical data, and 3 events bringing together key ACLF stakeholders. Results from UNVEIL-IT Phase 2 trial evaluating VS-01 in ACLF now expected in 2H25; protocol modified to improve recruitment and trial design. New insights and emerging scientific trends incorporated into our ACLF development plan, with data readout from 4 clinical trials anticipated by the end of 2025, including data from 3 new clinical trials to be launched in 1H25, in addition to UNVEIL-IT. U.S. launch progress is on-track after June 10, 2024 U.S. Foo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genfit-announces-corporate-updates-upcoming-211000020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CCA","BK4139","PBC","USA","GNFTF","GNFT","BK4095","NTZ"],"gpt_icon":0},{"id":"2483007512","title":"Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2483007512","media":"ACCESSWIRE","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483007512?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:00","pubTimestamp":1731502800,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc.  , a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric nanoparticles created for carrying therapeutic and targeting agents. With particular utility in cancer therapies, this innovative platform is designed to enhance the delivery of therapeutic antibodies and peptides, which are often limited by enzymatic degradation and poor systemic circulation.Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology and inflammation. The lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis , a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new ap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tharimmune-granted-european-patent-delivery-130000865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","PBC","THAR","BK4139"],"gpt_icon":1}],"pageSize":20,"totalPage":8,"pageCount":6,"totalSize":145,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-12-30","symbol":"PBC","reason":null,"defaultRemindTime":1640874600000,"announcedDate":"2021-12-01","type":"delisting","dateTimestamp":1640840400000},{"market":"US","date":"2021-11-30","symbol":"PBC","amount":0.4296875,"defaultRemindTime":1638282600000,"name":"Prospect Capital Corp","recordDate":"2021-12-15","payableDate":"2021-12-01","currency":"USD","type":"dividend","dateTimestamp":1638248400000},{"market":"US","date":"2021-08-31","symbol":"PBC","amount":0.4296875,"defaultRemindTime":1630416600000,"name":"Prospect Capital Corp","recordDate":"2021-09-15","payableDate":"2021-09-01","currency":"USD","type":"dividend","dateTimestamp":1630382400000},{"market":"US","date":"2021-05-28","symbol":"PBC","amount":0.4296875,"defaultRemindTime":1622208600000,"name":"Prospect Capital Corp","recordDate":"2021-06-15","payableDate":"2021-06-01","currency":"USD","type":"dividend","dateTimestamp":1622174400000},{"market":"US","date":"2021-02-26","symbol":"PBC","amount":0.4296875,"name":"Prospect Capital Corp","recordDate":"2021-03-15","payableDate":"2021-03-01","currency":"USD","type":"dividend","dateTimestamp":1614315600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBC\",market:\"US\",,,undefined,":[{"executeDate":"2019-02-28","recordDate":"2019-03-01","paymentDate":"2019-03-15","value":0.4774306,"currency":"USD"},{"executeDate":"2019-08-29","recordDate":"2019-08-30","paymentDate":"2019-09-15","value":0.4296875,"currency":"USD"},{"executeDate":"2019-11-27","recordDate":"2019-11-29","paymentDate":"2019-12-15","value":0.4296875,"currency":"USD"},{"executeDate":"2020-02-27","recordDate":"2020-02-28","paymentDate":"2020-03-15","value":0.4296875,"currency":"USD"},{"executeDate":"2020-05-29","recordDate":"2020-06-01","paymentDate":"2020-06-15","value":0.4296875,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBC\",market:\"US\",delay:false,,,undefined,":{}}}